|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
gptkb:Australia
gptkb:Europe
1997
|
|
gptkbp:ATCCode
|
N06AX18
|
|
gptkbp:brand
|
gptkb:Edronax
gptkb:Vestra
Norebox
|
|
gptkbp:CASNumber
|
gptkb:98769-83-2
|
|
gptkbp:chemicalClass
|
morpholine derivative
|
|
gptkbp:compatibleWith
|
gptkb:United_States
|
|
gptkbp:contraindication
|
seizure disorders
narrow angle glaucoma
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasEnantiomer
|
gptkb:(R,R)-reboxetine
gptkb:(S,S)-reboxetine
|
|
gptkbp:hasMolecularFormula
|
C19H23NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
reboxetine
|
|
gptkbp:IUPACName
|
gptkb:2-[(2-ethoxyphenoxy)benzyl]morpholine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
1982
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
|
|
gptkbp:proteinBinding
|
97%
|
|
gptkbp:PubChem_CID
|
77911
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
sweating
insomnia
tachycardia
dry mouth
urinary retention
|
|
gptkbp:synonym
|
gptkb:(R,R)-reboxetine
gptkb:racemic_reboxetine
|
|
gptkbp:UNII
|
2BT1O9VBU3
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:norepinephrine_transporter
|
|
gptkbp:bfsLayer
|
7
|